Autonomic Dysfunctions in Patients with Inflammatory Bowel Disease in Clinical Remission

被引:0
|
作者
Purnima Sharma
Govind K. Makharia
Vineet Ahuja
Sada Nand Dwivedi
Kishore Kumar Deepak
机构
[1] All India Institute of Medical Sciences,Department of Physiology
[2] All India Institute of Medical Sciences,Department of Gastroenterology and Human Nutrition
[3] All India Institute of Medical Sciences,Department of Biostatistics
来源
关键词
Crohn’s disease; Ulcerative colitis; Immune system; Chronic inflammation; Heart rate variability; Vagus nerve;
D O I
暂无
中图分类号
学科分类号
摘要
Introduction and Objective The autonomic nervous system, especially the parasympathetic system, has been reported to modulate the immune response in chronic inflammatory disorders. Autonomic dysfunctions have been reported earlier in patients with inflammatory bowel disease; however, the results have been conflicting. We therefore evaluated autonomic functions in patients with inflammatory bowel disease (IBD) in clinical remission. Patients and Methods Heart rate variability, a marker of autonomic functions, which included time-domain, frequency-domain, and nonlinear indices (Poincaré plot) was assessed using Nevrokard, version 6.4.0 Slovenia, in 118 patients with IBD (ulcerative colitis [UC] 62, and Crohn’s disease [CD] 56) and 58 healthy controls. Results There was no difference in mean of R–R intervals in patients with UC, CD, and healthy controls. Frequency domain indices (absolute values of total power, high-frequency power, and low-frequency power) were lower in patients with UC and CD vs. healthy controls. High-frequency (HFnu) (expressed in normalized units) was significantly lower in UC compared to healthy controls. There was no significant difference in the low-frequency (LFnu) and LF/HF ratio in UC, CD, and healthy controls. Amongst the Poincaré plot indices, while standard deviation of the instantaneous R–R interval variability (SD1nu) was lower in UC and CD vs. healthy controls, there was no significant difference in the long-term R–R interval variability (SD2nu). Conclusions Patients with inflammatory bowel disease have lower autonomic functions. Patients with UC have significantly lower parasympathetic function in comparison to those with CD and healthy controls. These autonomic dysfunctions in patients with IBD may have a bearing on the pathogenesis of IBD.
引用
收藏
页码:853 / 861
页数:8
相关论文
共 50 条
  • [1] Autonomic Dysfunctions in Patients with Inflammatory Bowel Disease in Clinical Remission
    Sharma, Purnima
    Makharia, Govind K.
    Ahuja, Vineet
    Dwivedi, Sada Nand
    Deepak, Kishore Kumar
    [J]. DIGESTIVE DISEASES AND SCIENCES, 2009, 54 (04) : 853 - 861
  • [2] NUTRITIONAL STATUS OF PATIENTS WITH INFLAMMATORY BOWEL DISEASE IN CLINICAL REMISSION
    Kusunoki, Ryusaku
    Kuwai, Toshio
    Kato, Naohiro
    Sugata, Shuhei
    Hamada, Takuro
    Furuya, Nao
    Mizumoto, Takeshi
    Tamaru, Yuzuru
    Yamaguchi, Atsushi
    Kouno, Hirotaka
    Kohno, Hiroshi
    [J]. GASTROENTEROLOGY, 2023, 164 (06) : S709 - S709
  • [3] Adalimumab is effective in patients with inflammatory bowel disease in clinical remission on infliximab
    Khan, M.
    Heetun, Z.
    Moloney, J.
    Courtney, G.
    Aftab, A. R.
    [J]. IRISH JOURNAL OF MEDICAL SCIENCE, 2015, 184 : S73 - S74
  • [4] Care of inflammatory bowel disease patients in remission
    Subramanian, Charumathi Raghu
    Triadafilopoulos, George
    [J]. GASTROENTEROLOGY REPORT, 2016, 4 (04): : 261 - 271
  • [5] Autonomic dysfunction of inflammatory bowel disease patients
    Bai, Aiping
    Wang, Li
    [J]. JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2013, 28 : 140 - 140
  • [6] Clinical Evidence of Autonomic Dysfunction in Inflammatory Bowel Disease
    Keller, Jutta
    Andresen, Viola
    Layer, Peter H.
    [J]. GASTROENTEROLOGY, 2010, 138 (05) : S623 - S624
  • [7] Acceptability of a 'treat to target' approach in inflammatory bowel disease to patients in clinical remission
    Selinger, Christian
    Carbonell, Jenelyn
    Kane, John
    Omer, Mandour
    Ford, Alexander Charles
    [J]. FRONTLINE GASTROENTEROLOGY, 2021, 12 (01) : 30 - 38
  • [8] Clinical outcomes of vedolizumab withdrawal in inflammatory bowel disease for patients in histological remission
    Blad, William
    Whitley, Lisa
    Harrow, Paul
    [J]. GUT, 2023, 72 (SUPPL_2) : A87 - A88
  • [9] Serum levels of selected micronutrients in patients with inflammatory bowel disease in clinical remission
    Piatek-Guziewicz, Agnieszka
    Pasko, Pawel
    Wcislo, Kacper
    Dabek-Drobny, Agnieszka
    Przybylska-Felus, Magdalena
    Kaczmarczyk, Olga
    Zagrodzki, Pawel
    Mach, Tomasz
    Zwolinska-Wcislo, Malgorzata
    [J]. POLISH ARCHIVES OF INTERNAL MEDICINE-POLSKIE ARCHIWUM MEDYCYNY WEWNETRZNEJ, 2021, 131 (7-8): : 701 - 708
  • [10] Majority of patients with inflammatory bowel disease in clinical remission have mucosal inflammation
    Baars, Judith E.
    Nuij, Veerle J. A. A.
    Oldenburg, Bas
    Kuipers, Ernst J.
    van der Woude, Christien J.
    [J]. INFLAMMATORY BOWEL DISEASES, 2012, 18 (09) : 1634 - 1640